PDF(Pubmed)
Abstract：
Objectives: The aim of this study was to determine the possible correlation between the short- and long-term effects of intravitreal bevacizumab on macular oedema after branch retinal vein occlusion (BRVO). Material and methods: This prospective clinical study included fifteen eyes of patients with macular oedema after BRVO. Corrected distance visual acuity (CDVA), recorded in LogMAR units, central foveal thickness (CFT) and maximum foveal thickness (MFT) were evaluated at one month after first application and at least every 2 months for one year. PRN treatment protocol was used for all patients. Statistical calculation was performed with SPSS for Windows and Microsoft Excel. Results: Mean CFT decreased significantly (p<0,0001) from baseline 471,2 ± 151,7 μm to 285,9 ± 79,82 μm at 12 months. CDVA improved significantly (p<0,0001) from baseline 0,58 ± 0,34 to 0,1 ± 0,25 at the end of follow up period. Change from baseline in the CDVA after one month was significantly positively correlated with the change in CDVA after 12 months (r=0,76, p=0,001). Change in CFT after one month had a strong positive correlation (r=0,78, p=0,001) with change after 12 months. There was no statistically significant correlation between the number of injections and the changes in CDVA, CFT, MFT after a single injection. Conclusions: Single injection effects of bevacizumab may indicate long-term results on macular oedema after BRVO, but further and larger studies are necessary. Abbreviations: BRVO = Branch retinal vein occlusion, RVO = Retinal vein occlusion, CFT = Central foveal thickness, MFT = Maximum foveal thickness, VEGF = Vascular endothelial growth factor, MO = Macular oedema, CDVA = Corrected distance visual acuity, PRN = Pro-re-Nata, SD-OCT = Special-domain optical coherence tomography, FT = Foveal thickness, LogMAR = Logarithm of the Minimum Angle of Resolution, WHO = World Health Organization, RPE = Retinal pigment epithelium.
摘要：
目的：本研究的目的是确定玻璃体内贝伐单抗对视网膜分支静脉阻塞（BRVO）后黄斑水肿的短期和长期影响之间的可能相关性。材料和方法：这项前瞻性临床研究包括15只眼BRVO术后黄斑水肿患者。校正后的远距视力(CDVA),以LogMAR单位记录，中心凹厚度(CFT)和最大中心凹厚度(MFT)在首次应用后1个月进行评估,并至少每2个月进行1年.所有患者均采用PRN治疗方案。用SPSSforWindows和MicrosoftExcel进行统计计算。结果:在12个月时,平均CFT从基线471,2±151,7μm显著降低(p<0,0001)至285,9±79,82μm。在随访期结束时,CDVA从基线0,58±0,34显著改善(p<0,0001)至0,1±0,25。1个月后CDVA相对于基线的变化与12个月后CDVA的变化呈显著正相关(r=0,76,p=0,001)。一个月后CFT的变化与12个月后的变化具有很强的正相关（r=0,78，p=0,001）。注射次数与CDVA变化无统计学意义的相关性,CFT,单次注射后的MFT。结论：单次注射贝伐单抗可能表明BRVO后黄斑水肿的长期结果，但进一步和更大的研究是必要的。缩写：BRVO=视网膜分支静脉阻塞，RVO=视网膜静脉阻塞,CFT=中央凹厚度，MFT=最大中央凹厚度，VEGF=血管内皮生长因子，MO=黄斑水肿，CDVA=校正后的远距视力,PRN=Pro-re-Nata，SD-OCT=特殊域光学相干断层扫描,FT=中心凹厚度,LogMAR=最小分辨角度的对数，WHO=世界卫生组织，RPE=视网膜色素上皮。
